A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
作者信息
Steen Chloé B, Leich Ellen, Myklebust June H, Lockmer Sandra, Wise Jillian F, Wahlin Björn E, Østenstad Bjørn, Liestøl Knut, Kimby Eva, Rosenwald Andreas, Smeland Erlend B, Holte Harald, Lingjærde Ole Christian, Brodtkorb Marianne
机构信息
Department of Informatics, University of Oslo, Oslo, Norway.
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
出版信息
Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7.
Abstract
摘要
相似文献
1
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.一种临床分子预测指标可识别一线免疫治疗后有早期转化风险的滤泡性淋巴瘤患者。
Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7.
2
Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10.伴有CD5和CD10共表达的滤泡性淋巴瘤的原淋巴细胞样转化
Leuk Lymphoma. 2006 Mar;47(3):541-7. doi: 10.1080/10520290500305310.
3
Progression of follicular large cell lymphoma to Burkitt's lymphoma.滤泡性大细胞淋巴瘤进展为伯基特淋巴瘤。
Cancer. 1989 Feb 15;63(4):700-2. doi: 10.1002/1097-0142(19890215)63:4<700::aid-cncr2820630417>3.0.co;2-s.
4
miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.在滤泡性淋巴瘤转化过程中，miR-31和miR-17-5p水平发生变化。
Hum Pathol. 2016 Apr;50:118-26. doi: 10.1016/j.humpath.2015.11.011. Epub 2015 Nov 30.
5
Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis.健康个体中的滤泡性淋巴瘤样B细胞：早期淋巴瘤发生的一个新的中间阶段。
J Exp Med. 2006 Oct 30;203(11):2425-31. doi: 10.1084/jem.20061292. Epub 2006 Oct 16.
6
Long-term survival after histologic transformation of low-grade follicular lymphoma.低级别滤泡性淋巴瘤组织学转化后的长期生存情况。
J Clin Oncol. 1995 Jul;13(7):1726-33. doi: 10.1200/JCO.1995.13.7.1726.
7
Novel acquisitions on biology and management of transformed follicular lymphoma.滤泡性淋巴瘤转化的生物学和治疗新进展。
Hematol Oncol. 2018 Oct;36(4):617-623. doi: 10.1002/hon.2508. Epub 2018 Mar 30.
8
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.在接受一线免疫化疗的滤泡性淋巴瘤患者中，基因突变更新预后风险预测：一项前瞻性临床试验的回顾性分析及基于人群的登记处验证。
Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.
9
Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.滤泡性淋巴瘤：重新定义预后、当前治疗选择和未满足的需求。
Hematol Oncol Clin North Am. 2019 Aug;33(4):627-638. doi: 10.1016/j.hoc.2019.03.003. Epub 2019 May 18.
10
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation.利妥昔单抗作为“体内净化”及自体干细胞移植后巩固性免疫疗法治疗滤泡性或套细胞淋巴瘤患者的药代动力学研究
Ann Oncol. 2003 May;14(5):758-65. doi: 10.1093/annonc/mdg201.
引用本文的文献
1
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.分子生物标志物在预测滤泡性淋巴瘤患者高级别转化和结局中的作用：一项全面的系统性综述。
Int J Mol Sci. 2024 Oct 17;25(20):11179. doi: 10.3390/ijms252011179.
2
Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era.免疫格局在滤泡性淋巴瘤中的影响：利妥昔单抗时代组织学转化的见解
Cancers (Basel). 2024 Oct 21;16(20):3553. doi: 10.3390/cancers16203553.
3
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.多组学纵向样本分析揭示滤泡性淋巴瘤早期的基因组变化。
Blood Cancer J. 2024 Aug 27;14(1):147. doi: 10.1038/s41408-024-01124-5.
4
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.B 细胞非霍奇金淋巴瘤肿瘤内调节性 T 细胞的异质性。
Blood Adv. 2023 Dec 12;7(23):7216-7230. doi: 10.1182/bloodadvances.2023010158.
本文引用的文献
1
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.晚期惰性淋巴瘤的无化疗初始治疗具有持久疗效且毒性低：两项北欧淋巴瘤小组试验超过10年随访结果
J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
2
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.通过单细胞分析确定非霍奇金淋巴瘤中B细胞受体信号传导的不同模式。
Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.
3
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.B细胞受体信号传导和经典核因子κB激活在套细胞淋巴瘤中的致病作用
Blood. 2016 Jul 7;128(1):82-92. doi: 10.1182/blood-2015-11-681460. Epub 2016 Apr 28.
4
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.在接受一线免疫化疗的滤泡性淋巴瘤患者中，基因突变更新预后风险预测：一项前瞻性临床试验的回顾性分析及基于人群的登记处验证。
Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.
5
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.利妥昔单抗联合或不联合干扰素-α2a进行的两个疗程、每周一次共四周的输注：一项针对有症状的惰性B细胞淋巴瘤的随机III期研究的最终结果
Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11.
6
Transformed follicular non-Hodgkin lymphoma.转化滤泡性非霍奇金淋巴瘤。
Blood. 2015 Jan 1;125(1):40-7. doi: 10.1182/blood-2014-04-516815. Epub 2014 Dec 11.
7
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.全基因组整合分析揭示了预测滤泡性淋巴瘤转化的表达特征。
Blood. 2014 Feb 13;123(7):1051-4. doi: 10.1182/blood-2013-07-512392. Epub 2013 Dec 19.
8
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.免疫化疗时代滤泡性淋巴瘤转化的发生率和结局：来自爱荷华大学/梅奥诊所卓越研究计划分子流行病学资源的报告。
J Clin Oncol. 2013 Sep 10;31(26):3272-8. doi: 10.1200/JCO.2012.48.3990. Epub 2013 Jul 29.
9
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.4 个十年期间滤泡性 1-2 级淋巴瘤观察到和相对生存率的改善：斯坦福大学的经验。
Blood. 2013 Aug 8;122(6):981-7. doi: 10.1182/blood-2013-03-491514. Epub 2013 Jun 18.
10
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中慢性活性 B 细胞受体信号转导。
Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.
Zotero 插件